361 related articles for article (PubMed ID: 27493449)
21. Blocking only the bad side of IL-6 in inflammation and cancer.
Rose-John S
Cytokine; 2021 Dec; 148():155690. PubMed ID: 34474215
[TBL] [Abstract][Full Text] [Related]
22. Cytokines are a therapeutic target for the prevention of inflammation-induced cancers.
Rose-John S; Schooltink H
Recent Results Cancer Res; 2007; 174():57-66. PubMed ID: 17302185
[TBL] [Abstract][Full Text] [Related]
23. Proteolytic Cleavage Governs Interleukin-11 Trans-signaling.
Lokau J; Nitz R; Agthe M; Monhasery N; Aparicio-Siegmund S; Schumacher N; Wolf J; Möller-Hackbarth K; Waetzig GH; Grötzinger J; Müller-Newen G; Rose-John S; Scheller J; Garbers C
Cell Rep; 2016 Feb; 14(7):1761-1773. PubMed ID: 26876177
[TBL] [Abstract][Full Text] [Related]
24. Interleukin-6 trans-signalling in chronic inflammation and cancer.
Scheller J; Ohnesorge N; Rose-John S
Scand J Immunol; 2006 May; 63(5):321-9. PubMed ID: 16640655
[TBL] [Abstract][Full Text] [Related]
25. Soluble interleukin-6 receptor alpha inhibits the cytokine-Induced fractalkine/CX3CL1 expression in human vascular endothelial cells in culture.
Matsumiya T; Imaizumi T; Fujimoto K; Cui X; Shibata T; Tamo W; Kumagai M; Tanji K; Yoshida H; Kimura H; Satoh K
Exp Cell Res; 2001 Sep; 269(1):35-41. PubMed ID: 11525637
[TBL] [Abstract][Full Text] [Related]
26. Soluble interleukin-6 receptor (sIL-6R) in cerebrospinal fluid of patients with inflammatory and non inflammatory neurological diseases.
Michalopoulou M; Nikolaou C; Tavernarakis A; Alexandri NM; Rentzos M; Chatzipanagiotou S; Cambouri C; Vassilopoulos D
Immunol Lett; 2004 Jul; 94(3):183-9. PubMed ID: 15275965
[TBL] [Abstract][Full Text] [Related]
27. The Soluble Interleukin 6 Receptor: Advanced Therapeutic Options in Inflammation.
Rose-John S
Clin Pharmacol Ther; 2017 Oct; 102(4):591-598. PubMed ID: 28675418
[TBL] [Abstract][Full Text] [Related]
28. sIL-6R: more than an agonist?
Knüpfer H; Preiss R
Immunol Cell Biol; 2008 Jan; 86(1):87-91. PubMed ID: 17724457
[TBL] [Abstract][Full Text] [Related]
29. Cathepsin S provokes interleukin-6 (IL-6) trans-signaling through cleavage of the IL-6 receptor in vitro.
Flynn CM; Garbers Y; Düsterhöft S; Wichert R; Lokau J; Lehmann CHK; Dudziak D; Schröder B; Becker-Pauly C; Rose-John S; Aparicio-Siegmund S; Garbers C
Sci Rep; 2020 Dec; 10(1):21612. PubMed ID: 33303781
[TBL] [Abstract][Full Text] [Related]
30. Interleukin-6 receptor signaling. II. Bio-availability of interleukin-6 in serum.
Gaillard J; Pugnière M; Tresca J; Mani J; Klein B; Brochier J
Eur Cytokine Netw; 1999 Sep; 10(3):337-44. PubMed ID: 10477390
[TBL] [Abstract][Full Text] [Related]
31. The interleukin-6 receptor Asp358Ala single nucleotide polymorphism rs2228145 confers increased proteolytic conversion rates by ADAM proteases.
Garbers C; Monhasery N; Aparicio-Siegmund S; Lokau J; Baran P; Nowell MA; Jones SA; Rose-John S; Scheller J
Biochim Biophys Acta; 2014 Sep; 1842(9):1485-94. PubMed ID: 24878322
[TBL] [Abstract][Full Text] [Related]
32. Role of the IL-6 classic- and trans-signaling pathways in corneal sterile inflammation and wound healing.
Ebihara N; Matsuda A; Nakamura S; Matsuda H; Murakami A
Invest Ophthalmol Vis Sci; 2011 Nov; 52(12):8549-57. PubMed ID: 21989726
[TBL] [Abstract][Full Text] [Related]
33. Major role of the soluble interleukin-6/interleukin-6 receptor complex for the proliferation of interleukin-6-dependent human myeloma cell lines.
Gaillard JP; Liautard J; Klein B; Brochier J
Eur J Immunol; 1997 Dec; 27(12):3332-40. PubMed ID: 9464821
[TBL] [Abstract][Full Text] [Related]
34. Dissecting Interleukin-6 Classic- and Trans-Signaling in Inflammation and Cancer.
Garbers C; Rose-John S
Methods Mol Biol; 2018; 1725():127-140. PubMed ID: 29322414
[TBL] [Abstract][Full Text] [Related]
35. Activation of the signal transducer glycoprotein 130 by both IL-6 and IL-11 requires two distinct binding epitopes.
Kurth I; Horsten U; Pflanz S; Dahmen H; Küster A; Grötzinger J; Heinrich PC; Müller-Newen G
J Immunol; 1999 Feb; 162(3):1480-7. PubMed ID: 9973404
[TBL] [Abstract][Full Text] [Related]
36. Cleavage of the Interleukin-11 receptor induces processing of its C-terminal fragments by the gamma-secretase and the proteasome.
Lokau J; Flynn CM; Garbers C
Biochem Biophys Res Commun; 2017 Sep; 491(2):296-302. PubMed ID: 28735867
[TBL] [Abstract][Full Text] [Related]
37. Trans-signaling of interleukin-6 (IL-6) is mediated by the soluble IL-6 receptor, but not by soluble CD5.
Aparicio-Siegmund S; Deseke M; Lickert A; Garbers C
Biochem Biophys Res Commun; 2017 Mar; 484(4):808-812. PubMed ID: 28159554
[TBL] [Abstract][Full Text] [Related]
38. Interleukin-6 controls recycling and degradation, but not internalization of its receptors.
Flynn CM; Kespohl B; Daunke T; Garbers Y; Düsterhöft S; Rose-John S; Haybaeck J; Lokau J; Aparicio-Siegmund S; Garbers C
J Biol Chem; 2021; 296():100434. PubMed ID: 33610555
[TBL] [Abstract][Full Text] [Related]
39. Dissecting Interleukin-6 Classic and Trans-signaling in Inflammation and Cancer.
Garbers C; Rose-John S
Methods Mol Biol; 2023; 2691():207-224. PubMed ID: 37355548
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic blockade of the interleukin-6 receptor (IL-6R) allows sIL-6R generation by proteolytic cleavage.
Prenissl N; Lokau J; Rose-John S; Haybaeck J; Garbers C
Cytokine; 2019 Feb; 114():1-5. PubMed ID: 30557809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
